Valuation: Novacyt

Capitalization 40.08M 42.07M 37.58M 33.33M 59.89M 3.57B 66.2M 462M 171M 1.47B 158M 155M 6.46B P/E ratio 2022
-2.99x
P/E ratio 2023 -1.54x
Enterprise value 9.72M 10.2M 9.11M 8.08M 14.53M 865M 16.06M 112M 41.45M 357M 38.34M 37.48M 1.57B EV / Sales 2022
-0.44x
EV / Sales 2023 1.15x
Free-Float
96.82%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.29%
1 week+7.36%
Current month+18.89%
1 month+15.68%
3 months-13.93%
6 months+12.09%
Current year-3.79%
More quotes
1 week
0.60
Extreme 0.595
0.74
1 month
0.54
Extreme 0.542
0.74
Current year
0.49
Extreme 0.4932
1.59
1 year
0.49
Extreme 0.4932
1.59
3 years
0.42
Extreme 0.42
5.08
5 years
0.12
Extreme 0.115
13.96
10 years
0.06
Extreme 0.0612
13.96
More quotes
Director TitleAgeSince
Chief Executive Officer 51 2024-04-30
Director of Finance/CFO 41 2019-12-31
Chief Tech/Sci/R&D Officer 50 -
Manager TitleAgeSince
Director/Board Member 73 2006-07-02
Director/Board Member 57 2017-06-26
Director/Board Member 41 2024-01-01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.29%+7.36%-7.30%-83.58%50.91M
-3.02%-5.42%+10.17%+40.41%1.39B
-0.06%-3.38%-27.77%-45.64%120M
Average -1.12%+12.18%-8.30%-29.60% 519.29M
Weighted average by Cap. -2.70%+1.54%+6.68%+29.74%
See all sector performances

Financials

2022 2023
Net sales 21.04M 22.08M 19.73M 17.5M 31.44M 1.87B 34.75M 243M 89.72M 772M 82.98M 81.12M 3.39B 11.58M 12.15M 10.86M 9.63M 17.3M 1.03B 19.13M 134M 49.38M 425M 45.67M 44.64M 1.87B
Net income -25.73M -27.01M -24.13M -21.4M -38.45M -2.29B -42.5M -297M -110M -944M -101M -99.21M -4.15B -28.29M -29.7M -26.53M -23.53M -42.28M -2.52B -46.73M -326M -121M -1.04B -112M -109M -4.56B
Net Debt -86.29M -90.58M -80.91M -71.76M -129M -7.68B -143M -995M -368M -3.17B -340M -333M -13.92B -30.36M -31.87M -28.47M -25.25M -45.37M -2.7B -50.14M -350M -129M -1.11B -120M -117M -4.9B
More financial data * Estimated data
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Employees
240
More about the company
Date Price Change Volume
24-12-13 0.6860 -0.29% 550,775
24-12-12 0.6880 -5.23% 973,124
24-12-11 0.7260 +17.67% 1,516,448
24-12-10 0.6170 -0.48% 238,715
24-12-09 0.6200 -2.97% 1,244,156

Real-time Euronext Paris, December 13, 2024 at 11:35 am EST

More quotes

Annual profits - Rate of surprise